FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899003800> ?p ?o ?g. }

• W2899003800 endingPage "103" @default.
• W2899003800 startingPage "94" @default.
• W2899003800 abstract "Background: Direct-acting antiviral therapy for hepatitis C virus (HCV) infection is safe and effective, but there are little data among people who have recently injected drugs. This study evaluated the efficacy, and safety of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin for chronic HCV genotype (G) 1 among people with recent injecting drug use and/or receiving OST. Methods: D3FEAT is an international open-label study that recruited treatment-naïve participants with recent injecting drug use (previous 6 months) and/or receiving OST with chronic HCV G1 infection between June 2016 and February 2017 in seven countries. Participants received paritaprevir/ritonavir, ombitasvir, dasabuvir with (G1a) or without ribavirin (G1b) administered twice daily in a one-week electronic blister pack (records timing of each dose) for 12 weeks. The primary endpoint was undetectable HCV RNA 12 weeks post-treatment (SVR12). Results: Among 87 participants (median age 48 years), 23% were female, 8% had cirrhosis, and 90% had G1a. Overall, 71% were receiving OST, 61% injected in the previous six months, 45% injected in the previous month, and 15% injected > daily. Treatment completion was 97% (84 of 87). There were no virological breakthroughs, but three discontinuations (loss to follow-up, n = 1; non-adherence, n = 1; incarceration, n = 1). SVR was 91% (79 of 87, 95% CI, 83%–96%). Five participants who completed treatment did not have SVR (loss to follow-up, n = 1; death, n = 1; virologic relapse, n = 3). Drug use prior to and during treatment did not impact SVR12. Treatment-related adverse events were observed in 46 (53%) patients (six grade 3, no grade 4). Five (6%) patients had at least one serious adverse event (two possibly/probably related to therapy; nausea and myoclonus). Two cases of reinfection were observed. Conclusion: Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for 12 weeks is effective among people with HCV genotype 1 with recent injecting drug use and/or receiving OST." @default.
• W2899003800 created "2018-11-09" @default.
• W2899003800 creator A5008990660 @default.
• W2899003800 creator A5009499168 @default.
• W2899003800 creator A5009520658 @default.
• W2899003800 creator A5009631266 @default.
• W2899003800 creator A5011366248 @default.
• W2899003800 creator A5011527809 @default.
• W2899003800 creator A5013176250 @default.
• W2899003800 creator A5018402214 @default.
• W2899003800 creator A5019902771 @default.
• W2899003800 creator A5020475843 @default.
• W2899003800 creator A5027714342 @default.
• W2899003800 creator A5028544789 @default.
• W2899003800 creator A5028829460 @default.
• W2899003800 creator A5029095411 @default.
• W2899003800 creator A5030105607 @default.
• W2899003800 creator A5033057176 @default.
• W2899003800 creator A5033798070 @default.
• W2899003800 creator A5034351553 @default.
• W2899003800 creator A5043697753 @default.
• W2899003800 creator A5044560216 @default.
• W2899003800 creator A5045529959 @default.
• W2899003800 creator A5049864482 @default.
• W2899003800 creator A5052909853 @default.
• W2899003800 creator A5054107081 @default.
• W2899003800 creator A5056618727 @default.
• W2899003800 creator A5061560140 @default.
• W2899003800 creator A5062480277 @default.
• W2899003800 creator A5070585467 @default.
• W2899003800 creator A5083442088 @default.
• W2899003800 date "2018-12-01" @default.
• W2899003800 modified "2023-09-25" @default.
• W2899003800 title "Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy" @default.
• W2899003800 cites W1727788371 @default.
• W2899003800 cites W1801566764 @default.
• W2899003800 cites W1973675889 @default.
• W2899003800 cites W1989470432 @default.
• W2899003800 cites W2001458978 @default.
• W2899003800 cites W2006747389 @default.
• W2899003800 cites W2027498662 @default.
• W2899003800 cites W2040277070 @default.
• W2899003800 cites W2043193067 @default.
• W2899003800 cites W2047156711 @default.
• W2899003800 cites W2055154062 @default.
• W2899003800 cites W2113428683 @default.
• W2899003800 cites W2113636405 @default.
• W2899003800 cites W2115399503 @default.
• W2899003800 cites W2121737909 @default.
• W2899003800 cites W2141933812 @default.
• W2899003800 cites W2167150962 @default.
• W2899003800 cites W2170706646 @default.
• W2899003800 cites W2172036914 @default.
• W2899003800 cites W2258490349 @default.
• W2899003800 cites W2336440969 @default.
• W2899003800 cites W2345197548 @default.
• W2899003800 cites W2407455528 @default.
• W2899003800 cites W2514263904 @default.
• W2899003800 cites W2518041763 @default.
• W2899003800 cites W2518485884 @default.
• W2899003800 cites W2566331999 @default.
• W2899003800 cites W2578013986 @default.
• W2899003800 cites W2588375831 @default.
• W2899003800 cites W2602019447 @default.
• W2899003800 cites W2613090373 @default.
• W2899003800 cites W2620881498 @default.
• W2899003800 cites W2621337851 @default.
• W2899003800 cites W2625414995 @default.
• W2899003800 cites W2626989754 @default.
• W2899003800 cites W2748078120 @default.
• W2899003800 cites W2750028296 @default.
• W2899003800 cites W2765348434 @default.
• W2899003800 cites W2782256918 @default.
• W2899003800 cites W4241616429 @default.
• W2899003800 cites W982677670 @default.
• W2899003800 doi "https://doi.org/10.1016/j.drugpo.2018.10.004" @default.
• W2899003800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30384028" @default.
• W2899003800 hasPublicationYear "2018" @default.
• W2899003800 type Work @default.
• W2899003800 sameAs 2899003800 @default.
• W2899003800 citedByCount "21" @default.
• W2899003800 countsByYear W28990038002018 @default.
• W2899003800 countsByYear W28990038002019 @default.
• W2899003800 countsByYear W28990038002020 @default.
• W2899003800 countsByYear W28990038002021 @default.
• W2899003800 countsByYear W28990038002022 @default.
• W2899003800 countsByYear W28990038002023 @default.
• W2899003800 crossrefType "journal-article" @default.
• W2899003800 hasAuthorship W2899003800A5008990660 @default.
• W2899003800 hasAuthorship W2899003800A5009499168 @default.
• W2899003800 hasAuthorship W2899003800A5009520658 @default.
• W2899003800 hasAuthorship W2899003800A5009631266 @default.
• W2899003800 hasAuthorship W2899003800A5011366248 @default.
• W2899003800 hasAuthorship W2899003800A5011527809 @default.
• W2899003800 hasAuthorship W2899003800A5013176250 @default.
• W2899003800 hasAuthorship W2899003800A5018402214 @default.
• W2899003800 hasAuthorship W2899003800A5019902771 @default.
• W2899003800 hasAuthorship W2899003800A5020475843 @default.

• next